The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
A definitive model for predicting absolute risk of coronary heart disease (CHD) in male and female people with Type II diabetes is not yet available. This paper provides an equation for estimating the risk of new CHD events in people with Type II diabetes, based on data from 4540 U.K. Prospective Diabetes Study male and female patients. Unlike previously published risk equations, the model is diabetes-specific and incorporates glycaemia, systolic blood pressure and lipid levels as risk factors, in addition to age, sex, ethnic group, smoking status and time since diagnosis of diabetes. All variables included in the final model were statistically significant (P<0.001, except smoking for which P=0.0013) in likelihood ratio testing. This model provides the estimates of CHD risk required by current guidelines for the primary prevention of CHD in Type II diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The lower the CAD risk, the higher the chance of a false positive”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [248]
In the citing paper
“During the entire follow-up period, the rate of death among patients in the conventionaltherapy group was 50%, a finding that underscores the poor prognosis for such patients in the absence of intensive treatment.20”
From Effect of a multifactorial intervention on mortality in type 2 diabetes (2008) · cites this paper as [20]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Self-citationPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Cited by
Items 401–500 of 1,000
Low-cost preventive screening using carotid ultrasound in patients with diabetes
Suri, J. S. (2020) · Frontiers in bioscience · doi:10.2741/4850 · Cited by 40
“The various conventional screening tools for the assessment of CVD are: the Framingham Risk Score (16), Atherosclerotic Cardiovascular Disease (ASCVD) (19), Systematic Coronary Risk Evaluation (SCORE) risk chart (22), QRISK3 (52), the United Kingdom Prospective Diabetes Studies: UKPDS56 (17) and UKPDS60 (18), Reynolds…”
BackgroundInfluentialIntegration of cardiovascular risk assessment with COVID-19 using artificial intelligence
Suri, J. S., Puvvula, A., Majhail, M., Biswas, M., Jamthikar, A. D., Saba, L., Faa, G., Singh, I. M., Oberleitner, R., Turk, M., et al. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.04.236 · Cited by 38
“shown to be stronger than conventional cardiovascular risk calculators (CCVRC) (Conroy, 2003; Goff et al., 2014; Hippisley-Cox et al., 2017; Kothari et al., 2002; D’Agostino et al., 2008; Ridker et al., 2007; Stevens et al., 2001) because AtheroEdgeTM 2.”
BackgroundResultInfluentialHayashi, T., Hirano, T., Yamamoto, T., Ito, Y., & Adachi, M. (2006) · Metabolism · doi:10.1016/j.metabol.2006.02.014 · Cited by 38
“The United Kingdom Prospective Diabetes Study confirmed that intensive glycemic control delays the onset and retards the progression of microvascular disease, and possibly CHD, in patients with type 2 diabetes mellitus [1].”
BackgroundAntihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register
Eliasson, B., Eeg‐Olofsson, K., Cederholm, J., Nilsson, P. M., & Guðbjörnsdóttir, S. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.02.003 · Cited by 39
Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus
Wootton, P. T. E., Stephens, J. W., Hurel, S. J., Durand, H., Cooper, J. A., Ninio, E., Humphries, S. E., & Talmud, P. J. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.12.009 · Cited by 37
The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study
Gillett, M., Brennan, A., Watson, P., Khunti, K., Davies, M., Mostafa, S., & Gray, L. J. (2015) · Health Technology Assessment · doi:10.3310/hta19330 · Cited by 36
“The impact of any difference in risk factors such as SBP, age and cholesterol identified by the two tests will be captured within the UKPDS risk equations which include these risk factors.(41,40) The UKPDS CHD risk equation also includes HbA1c but not FPG.”
BackgroundHernández‐Mijares, A., García-Malpartida, K., Solá-Izquierdo, E., Bañuls, C., Rocha, M., Gómez-Martínez, M. J., Mármol, R., & Víctor, V. M. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01705.x · Cited by 38
Valentine, W. J., Aagren, M., Haglund, M., Ericsson, Å., & Gschwend, M. H. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494810379290 · Cited by 34
“This is in line with published data indicating the BMI is not an independent risk factor for most macrovascular complications in diabetes patients (however, blood pressure and serum lipid levels are often captured) [26,27].”
ResultStarting Primary Prevention Earlier With Statins
Robinson, J. G. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.07.076 · Cited by 39
Kariuki, J. K., Imes, C. C., Engberg, S. J., Scott, P. W., Klem, M. L., & Cortés, Y. I. (2023) · JBI Evidence Synthesis · doi:10.11124/jbies-22-00356 · Cited by 46
Inhibition of Human Intestinal α-Glucosidases by Calystegines
Jocković, N., Fischer, W., Brandsch, M., Brandt, W., & Dräger, B. (2013) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf4010737 · Cited by 52
Einarson, T. R., Bereza, B. G., Acs, A., & Jensen, R. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1257977 · Cited by 36
Johansson, T., Keller, S., Winkler, H., Ostermann, T., Weitgasser, R., & Sönnichsen, A. C. (2015) · Journal of Diabetes Research · doi:10.1155/2016/3248547 · Cited by 34
“0) [19], change in body weight (body mass index (BMI)), and smoking cessation (self-reported).”
BackgroundRealization of a service for the long-term risk assessment of diabetes-related complications
Lagani, V., Chiarugi, F., Manousos, D., Verma, V., Fursse, J., Marias, K., & Tsamardinos, I. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.03.011 · Cited by 34
Wong, N. D., Patao, C., Malik, S., & Iloeje, U. H. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.12.042 · Cited by 34
A population model of diabetes and pre-diabetes
Boutayeb, A., & Chetouani, A. (2007) · International Journal of Computer Mathematics · doi:10.1080/00207160601167037 · Cited by 34
Viñals, C., Conget, I., Pané, A., Boswell, L., Perea, V., Blanco, J., Ruiz, S., Giménez, M., Vinagre, I., Esmatjes, E., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3320 · Cited by 35
Widen, E., Raben, T. G., Lello, L., & Hsu, S. D. H. (2021) · Genes · doi:10.3390/genes12070991 · Cited by 32
Ladhani, N. N. N., Majumdar, S. R., Johnson, J. A., Tsuyuki, R. T., Lewanczuk, R. Z., Spooner, R., & Simpson, S. H. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03673.x · Cited by 35
It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia
Valensi, P. E., & Cosson, E. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.01.001 · Cited by 34
Stark, R. G., Schunk, M. V., Meisinger, C., Rathmann, W., Leidl, R., Holle, R., & for the KORA Study Group (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1186 · Cited by 35
Hamarneh, Y. N. A., Tsuyuki, R. T., Jones, C., Manns, B., Tonelli, M. A., Scott‐Douglas, N., Jindal, K. K., Tink, W., & Hemmelgarn, B. R. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.07.012 · Cited by 38
Rallo, B. L., Blanco-Gonzalez, M., Casas-Ciria, I., Marín-Andrade, J. A., Mendez-Segovia, J. C., Moratalla, G., Quintero-Dominguez, R., Ramirez-Raya, M., Guerrero-Pinedo, M. J., & Aguilar‐Diosdado, M. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.09.028 · Cited by 39
Pignone, M. P., Sheridan, S., Lee, Y. Z., Kuo, J., Phillips, C. J., Mulrow, C. D., & Zeiger, R. (2004) · Preventive Cardiology · doi:10.1111/j.1520-037x.2004.2417.x · Cited by 34
Chen, T., Xiao, S., Chen, Z., Yang, Y., Yang, B., & Liu, N. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111079 · Cited by 39
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
Bergmark, B. A., Bhatt, D. L., Braunwald, E., Morrow, D. A., Steg, P. G., Gurmu, Y., Cahn, A., Mosenzon, O., Raz, I., Bohula, E., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1736 · Cited by 31
on behalf of the IP-SDM Team;, Yu, C. H. Y., Ke, C., Jovičić, A., Hall, S., & Straus, S. E. (2019) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-019-0898-5 · Cited by 36
Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study
Echouffo-Tcheugui, J. B., Daya, N. R., Ndumele, C. E., Matsushita, K., Hoogeveen, R. C., Ballantyne, C. M., Coresh, J., Shah, A. M., & Selvin, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05678-6 · Cited by 35
“Indeed, the addition of GDF-15 to diabetes-specific risk prediction tools such as the UK Prospective Diabetes Study (UKPDS) engine [40, 41] could be considered to refine HF risk stratification among individuals with diabetes.”
BackgroundDual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency
Guarnotta, V., Stefano, C. D., Santoro, A., Ciresi, A., Coppola, A., & Giordano, C. S. D. S. (2019) · Endocrine Connections · doi:10.1530/ec-19-0176 · Cited by 35
Proceedings of the 11th Python in Science Conference
(2012) · Proceedings of the Python in Science Conferences · doi:10.25080/majora-54c7f2c8-00d · Cited by 33
Cleveringa, F. G. W., Welsing, P. M. J., van den Donk, M., Gorter, K. J., Niessen, L. W., Rutten, G. E. H. M., & Redekop, K. (2009) · Diabetes Care · doi:10.2337/dc09-1232 · Cited by 36
“In the long run, DCP is more costly and leads to only slightly more health than current care, although it does result in significantly lower CHD costs.”
BackgroundInfluentialStatins for all patients with type 2 diabetes: not so soon
Garg, A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16907-9 · Cited by 33
Simonson, D. C., Vernon, A., Foster, K., Halperin, F., Patti, M. E., & Goldfine, A. B. (2019) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.03.038 · Cited by 30
Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus
Sasako, T., Yamauchi, T., & Ueki, K. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0325 · Cited by 35
“The largest effect on the cardiovascular risk calculated on the basis of the UK Prospective Diabetes Study (UKPDS) [21] was accounted for by changes in lipids among those in major risk factors [20].”
BackgroundKengne, A. P. (2013) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2013-078 · Cited by 39
“This approach in people with diabetes was initially used by the UKPDS investigators.(9,19) Available studies largely suggest that classical cardiovascular risk factors (including smoking, blood pressure and lipid variables) and even some novel risk factors,(16,20-23) affect the risk of CVD in similar ways in people wi…”
BackgroundMethodResultthe Australasian Peers for Progress Diabetes Project Investigators, Riddell, M. A., Dunbar, J., Absetz, P., Wolfe, R. S., Li, H., Brand, M., Aziz, Z., & Oldenburg, B. F. (2016) · BMC Public Health · doi:10.1186/s12889-016-3538-3 · Cited by 36
“The primary outcome measure was cardiovascular disease risk at 12 months using the United Kingdom Prospective Diabetes Study (UKPDS) 5 yr risk calculation [39].”
MethodReview on cardiovascular risk prediction
Ruwanpathirana, T., Owen, A., & Reid, C. M. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12110 · Cited by 31
Franch‐Nadal, J., Olmeda, P. R., Badorrey, B. B., Rodríguez‐Poncelas, A., de Tuero, G. C., & Mata‐Cases, M. (2014) · Family Practice · doi:10.1093/fampra/cmu048 · Cited by 37
Modeling of Diabetes and Its Clinical Impact
Fritzen, K., Heinemann, L., & Schnell, O. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818785642 · Cited by 34
Cardiovascular outcomes trials in type 2 diabetes: Time to include young adults
Ke, C., Shah, B. R., Luk, A. O., Di Ruggiero, E., & Chan, J. C. N. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13874 · Cited by 30
“2020;22:3–5. wileyonlinelibrary.com/journal/dom © 2019 John Wiley & Sons Ltd 3 outcomes.6 Furthermore, the use of cardiovascular events as the only clinical outcome may not fully reflect the multi-system burden of T2D nor the safety and efficacy profile of these medications.1 Sodium- glucose co-transporter-2 inhibitor…”
BackgroundInfluentialPousinho, S., Morgado, M., Plácido, A. I., Roque, F., Falcão, A. C., & Alves, G. (2020) · Pharmacy Practice · doi:10.18549/pharmpract.2020.3.2000 · Cited by 31
Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus
van Dieren, S., Nöthlings, U., van der Schouw, Y. T., Spijkerman, A. M. W., Rutten, G. E. H. M., van der A, D. L., Sluik, D., Weikert, C., Joost, H., Boeing, H., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1945-z · Cited by 31
“The UKPDS risk engine was used to calculate 5 year CVD risk [6].”
BackgroundMethodInfluentialChowdhury, M., Yeasmin, F., Rabi, D. M., Ronksley, P. E., & Turin, T. C. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025579 · Cited by 33
Neeser, K., bben, G. L., Siebert, U., & Schramm, W. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422050-00006 · Cited by 31
Fujihara, K., Suzuki, H., Sato, A., Ishizu, T., Kodama, S., Heianza, Y., Saito, K., IWASAKI, H. O., Kobayashi, K., Yatoh, S., et al. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.20487 · Cited by 32
Bertoluci, M. C., Netto, A. P., Pires, A. C., Pesaro, A. E. P., Schaan, B. D., Caramelli, B., Polanczyk, C. A., Junior, C. V. S., Gualandro, D. M., Malerbi, D. A. C., et al. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-58 · Cited by 34
Pang, X.-H., Han, J., Ye, W.-L., Sun, X., Ding, Y., Huang, W.-J., Zhao, Y.-M., Lou, H.-Y., Shan, L.-Z., Kang, Y.-X., et al. (2017) · International Journal of Endocrinology · doi:10.1155/2017/9620513 · Cited by 28
Cardiovascular risk reduction following metabolic and bariatric surgery
English, W. J., Spann, M. D., Aher, C. V., & Williams, D. B. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.88 · Cited by 33
“Table 1 shows the different risk assessment tools being used worldwide, with risk factors measured to determine CVD risk (7-13).”
BackgroundWebb, D. R., Khunti, K., Gray, L. J., Srinivasan, B. T., Farooqi, A., Wareham, N. J., Griffin, S., Davies, M. J., & for the ADDITION‐Leicester study group (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03441.x · Cited by 32
Ramsey, S. D., Clarke, L. D., Roberts, C. S., Sullivan, S. D., Johnson, S. J., & Liu, L. Z. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826040-00005 · Cited by 31
“Annual transition probabilities for primary stroke and The model considered the demographic and clin- CHD were derived from risk equations reported ical characteristics of patients with type 2 diabetes in from the UKPDS (United Kingdom Prospective Dithe US, accounting for practice patterns and cost abetes Study).[9,10…”
MethodThe role of global risk assessment in hypertension therapy
Grover, S. A., Hemmelgarn, B. R., Joseph, L., Milot, A., & Tremblay, G. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70283-5 · Cited by 35
McIntyre, R. S., Cragin, L. S., Sorensen, S. V., Naci, H., Baker, T., & Roussy, J. (2010) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2009.01189.x · Cited by 31
Rosland, A.-M. M., Piette, J. D., TRIVEDI, R. B., Kerr, E. A., STOLL, S. C., Tremblay, A. S., & Heisler, M. (2018) · Trials · doi:10.1186/s13063-018-2785-2 · Cited by 30
Cardiovascular risk algorithms in primary care: Results from the DETECT study
Grammer, T. B., Dressel, A., Gergei, I., Kleber, M. E., Laufs, U., Scharnagl, H., Nixdorff, U., Klotsche, J., Pieper, L., Pittrow, D. B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37092-7 · Cited by 35
Variabilidad en la estimación del riesgo coronario en la diabetes mellitus tipo 2
Mollet, J. J., Molist‐Brunet, N., Franch‐Nadal, J., Borraz, V. S., Barragán, L. S., & Giménez, R. G. (2005) · Atención Primaria · doi:10.1157/13071042 · Cited by 36
Therapy Insight: peripheral arterial disease and diabetes—from pathogenesis to treatment guidelines
Mohler, E. R. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0823 · Cited by 35
Padwal, R. S., Hemmelgarn, B. R., Khan, N. A., Grover, S., McAlister, F. A., McKay, D. W., Wilson, T. W., Penner, B., Burgess, E., Bolli, P., et al. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)70619-6 · Cited by 43
Farmer, A., Bobrow, K., Leon, N., Williams, N., Phiri, E., Namadingo, H., Cooper, S., Prince, J., Crampin, A., Besada, D., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-11874-7 · Cited by 29
“Secondary outcomes were the proportion of patients collecting 80% or more of their agreed-upon, diabetes-related medication derived from routine clinic data [15]; change in systolic blood pressure; change in lipids; a combined measure of cardiovascular risk based on HbA1c, lipids, and systolic blood pressure [16]; and…”
BackgroundGhosh, P., Kandhare, A. D., Raygude, K. S., Kumar, V. S., Rajmane, A. R., Adil, M., & Bodhankar, S. L. (2012) · Asian Pacific Journal of Tropical Disease · doi:10.1016/s2222-1808(12)60237-0 · Cited by 30
Nandish, S., Wyatt, J., Bailon, O., Smith, M., OLIVEROS, R. A., & CHILTON, R. J. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.015 · Cited by 32
Pascale, M., Murray, N. J., Bachmann, M. O., Barton, G., Clark, A., Howe, A. C., Greaves, C. J., & Sampson, M. (2017) · BMC Public Health · doi:10.1186/s12889-016-3929-5 · Cited by 31
Cardiovascular risk models for South Asian populations: a systematic review
Gopal, D. P., & Usher‐Smith, J. A. (2015) · International Journal of Public Health · doi:10.1007/s00038-015-0733-4 · Cited by 29
“1991), a modified version of the Framingham model (NICE 2008), the UKPDS developed in the UK between 1977 and 1991 in patients with known type 2 diabetes (Stevens et al. 2001) and QRISK2 developed from the electronic primary health care records of 2,290,000 patients registered with GPs in the UK (Hippisley-Cox et al.”
MethodRefitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK
McEwan, P. C., Bennett, H., Ward, T. T., & Bergenheim, K. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0225-z · Cited by 33
Barratt, R., Frost, G., Millward, D. J., & Truby, H. (2008) · British Journal of Nutrition · doi:10.1017/s0007114507839018 · Cited by 30
“To assess cardiovascular risk the UKPDS risk engine((16)) was used.”
MethodReducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?
Hermans, M. P., & Fruchart, J. (2010) · Clinical Lipidology · doi:10.2217/clp.10.65 · Cited by 34
Echouffo-Tcheugui, J. B., & Kengne, A. P. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.07.002 · Cited by 30
Voorham, J., Denig, P., Wolffenbuttel, B. H. R., & Haaijer‐Ruskamp, F. M. (2008) · Medical Care · doi:10.1097/mlr.0b013e31815b9da0 · Cited by 31
Wu, Y., He, J., Sun, X., Zhao, Y., Lou, H.-Y., Ji, X., Pang, X.-H., Shan, L., Kang, Y.-X., Xu, J., et al. (2017) · Medicine · doi:10.1097/md.0000000000008151 · Cited by 28
Viswanathan, V., Jamthikar, A. D., Gupta, D., Puvvula, A., Khanna, N. N., Saba, L., Višković, K., Mavrogeni, S. I., Turk, M., Laird, J. R., et al. (2020) · International Angiology · doi:10.23736/s0392-9590.20.04338-2 · Cited by 29
The Net Value of Health Care for Patients With Type 2 Diabetes, 1997 to 2005
Eggleston, K. N., Shah, N. D., Smith, S. A., Wagie, A. E., Williams, A. R., Grossman, J. H., Berndt, E. R., Long, K. H., Banerjee, R., & Newhouse, J. P. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-6-200909150-00003 · Cited by 34
Hayashino, Y., Shimbo, T., Tsujii, S., Ishii, H., Kondo, H., Nakamura, T., Nagata-Kobayashi, S., & Fukui, T. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.03.086 · Cited by 29
Arsenault, B. J., Pîbarot, P., & Després, J. (2008) · Cardiology · doi:10.1159/000165919 · Cited by 36
“and the United Kingdom Prospective Diabetes Study risk engine (to be used in patients with diabetes) have been developed to quickly identify high-risk individuals based on risk factor classification [”
BackgroundWan, Q., Harris, M., Zwar, N. A., & Vagholkar, S. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01769.x · Cited by 33
Introduction of IFCC reference method for calibration of HbA1c: implications for clinical care
Manley, S. E., John, W. G., & Marshall, S. M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01311.x · Cited by 28
Beard, A., Hofer, T. P., Downs, J. R., Lucatorto, M. A., Klamerus, M. L., Holleman, R. G., & Kerr, E. A. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966697 · Cited by 29
Feo, P. D., Fatone, C., Burani, P., Piana, N., Pazzagli, C., Battistini, D., Capezzali, D., Pippi, R., Chipi, B., & Mazzeschi, C. (2011) · PubMed · doi:10.3275/7857 · Cited by 30
Modelling the Economics of Type 2 Diabetes Mellitus Prevention: A Literature Review of Methods
Watson, P., Preston, L., Squires, H., Chilcott, J. B., & Brennan, A. (2014) · Applied Health Economics and Health Policy · doi:10.1007/s40258-014-0091-z · Cited by 32
“Herman/ Ackerman [16, 17] 2005/ 6 IGR RCT DPP [67] RCT UKPDS [63, 64]”
BackgroundMethodInfluentialJohansen, O. E., Gullestad, L. L., Blaasaas, K. G., Orvik, E., & Birkeland, K. I. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02198.x · Cited by 28
Reinhard, H., Hansen, P. R., Persson, F., Tarnow, L., Wiinberg, N., Kjær, A., Petersen, C., Winther, K., Parving, H. ‐., Rossing, P. R., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr009 · Cited by 27
“Finally, the UKPDSCHD risk engine scores for CAD were calculated for each patient and used in the analysis [26].”
MethodSADIKOT, S. M., & Mogensen, C. E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.004 · Cited by 27
“[14] R.”
MethodControversies in the cardiovascular management of type 2 diabetes
Opie, L. H., Yellon, D. M., & Gersh, B. J. (2010) · Heart · doi:10.1136/hrt.2010.214031 · Cited by 31
“The major factor was the ratio of total cholesterol to highdensity lipoprotein cholesterol (HDL-C), which accounted for 45% of the risk.(1) Next came the significance of systolic blood pressure (SBP), accounting for 33% of the risk while last was the glycosylated haemoglobin (HbA1c) at 22%.”
BackgroundLian, J., McGhee, S. M., So, C., Chau, J., Wong, C. K. H., Wong, W. C. W., & Lam, C. L. K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13485 · Cited by 29
Ser, K., Lee, W., Chen, J., Tsai, P.-L., Chen, S., & Lee, Y.-C. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.11.020 · Cited by 27
Verma, S., Sharma, A., Zinman, B., Ofstad, A. P., FITCHETT, D. H., Brueckmann, M., Wanner, C., Zwiener, I., George, J. T., Inzucchi, S. E., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14015 · Cited by 28
A Pen-and-Paper Coronary Risk Estimator for Office Use With Patients With Type 2 Diabetes
Christianson, T. J. H., Bryant, S. C., Weymiller, A., Smith, S. A., & Montori, V. M. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.5.632 · Cited by 27
Giardina, M., Azuaje, F. J., McCullagh, P. J., & Harper, R. (2006) · IEEE International Conference on Bioinformatics and Bioengineering (BIBE) · doi:10.1109/bibe.2006.253297 · Cited by 26
Adiposity markers and risk of coronary heart disease in patients with type 2 diabetes mellitus
Tonding, S. F., Silva, F. M., Antonio, J. P., de Azevedo, M. J., Canani, L. H. S., & de Almeida, J. C. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-124 · Cited by 30
“This score has been validated specifically for patients with diabetes [23] and provides an estimate of risk for a new CHD event and stroke (fatal and nonfatal) at 5 and 10 years [22].”
InfluentialCardiovascular Risk/Disease in Type 2 Diabetes Mellitus
Román, G., & Stoian, A. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97422 · Cited by 30
Yang, Y., Kim, H., Kim, S., & Moon, M. K. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.12 · Cited by 30
Whitfield, M., Gillett, M., Holmes, M., & Ogden, E. (2006) · Public Health · doi:10.1016/j.puhe.2006.10.012 · Cited by 26
The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes
Lowey, A., Moore, S. E., Norris, C., Wright, D. J., Silcock, J., & Hammond, P. J. (2007) · Pharmacy World & Science · doi:10.1007/s11096-007-9101-7 · Cited by 29
“Where cardiovascular risk factors cannot be adequately modified by changes in lifestyle, evidence demonstrates that the majority of patients will benefit from pharmacological treatment [4], with patients at highest absolute risk having the most to gain [5].”
BackgroundMethodvan der Leeuw, J., Visseren, F. L. J., Woodward, M., Zoungas, S., Kengne, A. P., van der Graaf, Y., Glasziou, P., Hamet, P., MacMahon, S., Poulter, N., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04421 · Cited by 26
Severity of coronary artery disease in type 2 diabetes mellitus: Does the timing matter?
Srinivasan, M. P., Kamath, P. K., Bhat, N. M., Pai, N. D., Bhat, R. U., Shah, T., Singhal, A., & Mahabala, C. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2015.08.004 · Cited by 29
Quan, J., Pang, D., Li, T. K., Choi, C. H., Siu, S. C., Tang, S. Y. H., Wat, N. M. S., Woo, J., Lau, Z. Y., Tan, K. B., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00731 · Cited by 28
Jamthikar, A. D., Gupta, D., Cuadrado‐Godia, E., Puvvula, A., Khanna, N. N., Saba, L., Višković, K., Mavrogeni, S. I., Turk, M., Laird, J. R., et al. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2020.01.16 · Cited by 27
“At present, conventional cardiovascular risk calculators (CCVRC) models are available that provide an estimate of 10-year CVD/stroke risk to the patients (5-11).”
BackgroundPROactive 06: cost‐effectiveness of pioglitazone in Type 2 diabetes in the UK
Valentine, W. J., Bottomley, J. M., Palmer, A. J., Brändle, M., FOOS, V., Williams, R., Dormandy, J., Yates, J., Tan, M. H., Massi‐Benedetti, M., et al. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02188.x · Cited by 27
Beale, S., Bagust, A., Shearer, A. T., Martin, A. A., & Hulme, L. J. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624001-00003 · Cited by 26
Prediction of cardiovascular risk in people with diabetes
Winocour, P. H., & Fisher, M. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00934.x · Cited by 27
Al‐Lawati, J., Barakat, M. N., Lawati, N. A., Al-Maskari, M. Y., Elsayed, M. K., Mikhailidis, D. P., & Al-Zakwani, I. S. (2012) · Angiology · doi:10.1177/0003319712458349 · Cited by 26
Salinero-Fort, M. Á., Andrés-Rebollo, F. J. S., Cárdenas‐Valladolid, J., Méndez‐Bailón, M., Chico-Moraleja, R. M., Pau, E. C. D. S., Jiménez‐Trujillo, I., Gómez-Campelo, I., de Burgos‐Lunar, C., de Miguel-Yanes, J. M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94121-8 · Cited by 25
Metadata
- Authors
- STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M.
- Affiliations
- University of Oxford (GB)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2001-12-01
- Volume
- 101
- Issue
- 6
- Pages
- 671
- ISSN
- 0143-5221 (ISSN-L)
- OpenAlex
- W2117191092
- Cited by
- 1,084
- References
- 51
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 10 · 2023: 33 · 2022: 44 · 2021: 60 · 2020: 46 · 2019: 42 · 2018: 47 · 2017: 42 · 2016: 39 · 2015: 60 · 2014: 66 · 2013: 68 · 2012: 59
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- coronary artery disease, type 2 diabetes, cardiovascular risk prediction, risk prediction model, glycemia, systolic blood pressure, serum lipids, primary prevention, smoking, sex differences
- MeSH terms
- Adult, Blood Pressure, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Lipids, Male, Middle Aged, Risk Factors, Smoking, Models, Statistical, Survival Rate, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.